Ritalin / Concerta / Focalin Tapering Guide
methylphenidate
Boxed Warning
High potential for abuse and dependence — Schedule II controlled substance. Misuse may cause sudden death or serious cardiovascular events.
Overview
Methylphenidate is a Schedule II stimulant for ADHD and narcolepsy. Multiple formulations vary in onset, duration, and abuse liability. Carries a black-box warning for abuse and dependence.
IR: 5mg, 10mg, 20mg; ER: 10-72mg depending on formulation
Tablets IR: 5mg, 10mg, 20mg; Tablets/capsules ER: 10-72mg (Concerta, Ritalin LA, Metadate CD, etc.); Patch (Daytrana): 10-30mg/9h; ODT (Cotempla XR-ODT); Oral solution; Focalin (dexmethylphenidate, the d-isomer): 2.5-40mg
Category C
Mechanism of Action
Inhibits dopamine and norepinephrine reuptake by binding to DAT and NET. Some weak release component at higher doses.
Taper Notes
Step-down by formulation strength over 1-3 weeks. Plan low-demand period for the rebound window.
Hyperbolic Tapering Guidance
Stimulant withdrawal is rarely dangerous but can be psychologically rough. Rebound depression should be expected and not over-treated with new psychotropics.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
Hours after last dose; full picture 1-3 days
3-7 days
1-3 weeks
Anhedonia and low motivation can persist 3-8 weeks
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (hypertensive crisis)
- Vasopressors — additive
- Tricyclics, SSRIs — may increase methylphenidate effects
Contraindications
- Recent MAOI use
- Severe hypertension, advanced cardiovascular disease
- Hyperthyroidism
Toxicity
Anorexia, insomnia, hypertension, tachycardia, agitation, psychosis (high dose or vulnerable individuals), growth suppression in children, abuse and dependence.
Pharmacokinetics
ADME Profile
Hepatic via carboxylesterase to inactive ritalinic acid.
~15%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Ritalin / Concerta / Focalin (methylphenidate) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Wilens TE, Adler LA, Adams J, et al. 2008 — Misuse and diversion of stimulants prescribed for ADHD (Journal of the American Academy of Child & Adolescent Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Clinician-facing deprescribing algorithms
- Royal College of Psychiatrists — ADHD resources — UK clinical guidance on adult ADHD pharmacotherapy
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Mad in America — stimulant coverage — Independent journalism on stimulant prescribing and discontinuation
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- Surviving Antidepressants — other medications forum — Community discussion of stimulant taper experiences
- RxISK — adverse drug reaction reporting — Independent database of stimulant adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.